Cidara Therapeutics/$CDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
$CDTX
Sector
Primary listing
Employees
38
Headquarters
Website
CDTX Metrics
BasicAdvanced
$2.7B
-
-$10.21
1.34
-
Price and volume
Market cap
$2.7B
Beta
1.34
52-week high
$121.21
52-week low
$10.28
Average daily volume
1.1M
Financial strength
Current ratio
16.455
Quick ratio
15.856
Long term debt to equity
0.167
Total debt to equity
0.466
Profitability
EBITDA (TTM)
-133.53
Management effectiveness
Return on assets (TTM)
-23.61%
Return on equity (TTM)
-37.05%
Valuation
Price to book
4.9
Price to tangible book (TTM)
4.9
Price to free cash flow (TTM)
-9.413
Free cash flow yield (TTM)
-10.62%
Free cash flow per share (TTM)
-11.221
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-59.32%
3-year earnings per share growth (CAGR)
-21.53%
10-year earnings per share growth (CAGR)
-21.66%
What the Analysts think about CDTX
Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.
Bulls say / Bears say
The Phase 2b NAVIGATE trial of CD388 achieved its main and all secondary efficacy goals, showing 76.1% protection at the 450 mg dose over 24 weeks, reducing risk for the asset before heading to Phase 3 (GlobeNewswire via Cidara Therapeutics).
Cidara completed an expanded public offering of 9.15 million shares at $44.00 each in June 2025, raising $402.5 million to finance its planned Phase 3 program, significantly strengthening its balance sheet (GlobeNewswire via Cidara Therapeutics).
Cidara's addition to the Russell 2000® and Russell 3000® indexes in June 2025 improves its visibility with institutional investors and could attract passive investment flows (GlobeNewswire via Cidara Therapeutics).
Research and development expenses rose sharply to $24.8 million in Q2 2025 from $6.7 million in Q2 2024, indicating a much faster cash burn as CD388 moves through costly late-stage development (GlobeNewswire via Cidara Therapeutics).
Collaboration revenue dropped to zero in Q2 2025 after the Janssen agreement ended in April 2024, highlighting the lack of recurring income and the company’s full reliance on equity financing for its operations (GlobeNewswire via Cidara Therapeutics).
Cidara posted a net loss of $25.7 million in Q2 2025, underlining continued unprofitability despite progress in the clinic and substantial fundraising (GlobeNewswire via Cidara Therapeutics).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CDTX Financial Performance
Revenues and expenses
CDTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $2.7B as of October 16, 2025.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of October 16, 2025.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of October 16, 2025.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.